DWA
PRVB

Dorsey Wright & Associates’s Provention Bio, Inc. Common Stock PRVB Stock Holding History

Dorsey Wright & Associates’s Portfolio PRVB Stock Details PRVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-2,970
Closed -$31.4K – 369
2022
Q4 		$31.4K Buy
+2,970
New +$24K 0.01% 173

Other funds holding PRVB

SC
Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

Dorsey Wright & Associates's PRVB Position: Q1 2023 in Review

Dorsey Wright & Associates sold out of Provention Bio, Inc. Common Stock (PRVB) in Q1 2023, closing a stake of 2,970 shares — an estimated $31.4K sold.

Dorsey Wright & Associates first reported a position in PRVB in Q4 2022 and held it in 1 quarter. The position peaked at $31.4K in Q4 2022. 182 funds tracked by Wall St. Rank hold PRVB as of Q1 2023.

  • Dorsey Wright & Associates reported no remaining Provention Bio, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Dorsey Wright & Associates sold 2,970 Provention Bio, Inc. Common Stock shares in Q1 2023, an estimated $31.4K.
  • Dorsey Wright & Associates first reported a position in Provention Bio, Inc. Common Stock in Q4 2022 and held it in 1 quarter.
  • Dorsey Wright & Associates's Provention Bio, Inc. Common Stock position peaked at $31.4K in Q4 2022.
  • 182 funds tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q1 2023.

Based on Dorsey Wright & Associates's 13F filing for Q1 2023, filed 20 Apr 2023.